Pivotal trial met primary and all key secondary endpoints Dupixent significantly reduced itch at 12 weeks, and nearly three times as many Dupixent patients experienced reductions in both itch and skin ...
April 21, 2025 – The FDA just approved the popular drug Dupixent for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular allergy meds ...
Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application (sBLA) seeking approval for Dupixent for treating bullous pemphigoid (BP), a ...
Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) on Sept. 8 reported detailed results from a phase 3 trial showing that Dupixent significantly reduced itch and skin lesions at 24 weeks ...
Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials About 75,000 adults in the U.S. living with prurigo nodularis are ...
Regeneron Pharmaceuticals and Sanofi have won European Commission expanded approval of their blockbuster anti-inflammatory drug Dupixent for certain patients with the inflammatory skin condition ...
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly ...
Sanofi said its dupixent drug achieved significant improvements for the treatment of two skin diseases. The French pharmaceutical company said Wednesday that the drug met the primary and all key ...
April 25 (Reuters) - AbbVie (ABBV.N), opens new tab said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals ...
A woman holds a test tube in front of displayed Abbvie logo in this illustration (Reuters) - AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to ...